← Eichor
Condition: Metastases To Soft Tissue Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Metastases To Soft Tissue

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

IVIM & OLINK in Sarcoma
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT05950594A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Phase 2/Phase 3 · 202 location(s) · National Cancer Institute (NCI) · NCT05691478Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
Phase 1/Phase 2 · 1 location(s) · Universitair Ziekenhuis Brussel · NCT03707808A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosar
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07477457A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT04222413A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
Phase 2 · 1 location(s) · QBiotics Group Limited · NCT05755113Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Phase 1 · 5 location(s) · Ankyra Therapeutics, Inc · NCT06171750A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 · 6 location(s) · Angiex, Inc. · NCT06440005Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07584499Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment
Phase N/A · 1 location(s) · The Netherlands Cancer Institute · NCT07522762Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Phase 1/Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT03965234Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Phase 2 · 2 location(s) · Hackensack Meridian Health · NCT05726383IDOV-Immune for Advanced Solid Tumors
Phase 1 · 5 location(s) · ViroMissile, Inc. · NCT06910657Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/
Phase N/A · 1 location(s) · University of Washington · NCT01050504
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.